Acromegaly Market Analysis, Share And Growth 2025 To 2034

 

With a focus on usability, this report equips professionals with the latest industry insights to stay ahead in the competitive acromegaly market.

Acromegaly Market Valuation Forecast: What Will The Market Be Worth By 2025?
The acromegaly market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increasing prevalence of acromegaly therapeutics, growing awareness about acromegaly, government initiatives, demand for effective treatments.

The acromegaly market size is expected to see rapid growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to investments in research and development activities for acromegaly treatments, growing number of screening programs, rising healthcare spending, increasing demand for minimally invasive treatment options. Major trends in the forecast period include innovative treatments for acromegaly, development of targeted therapies for acromegaly, strong pipeline of drugs, advancements in treatment options, advanced personalized medicine.

Get your free sample today:
Growth & Share Analysis Sample

What Are The Key Factors Driving Growth In The Acromegaly Market?
The growing number of hormonal diseases such as diabetes is expected to propel the growth of the acromegaly market going forward. Hormonal diseases, also known as endocrine disorders, are medical conditions that result from dysfunction in the endocrine system. Diabetes is one of the most prevalent and significant hormonal diseases. Acromegaly and other endocrine diseases can result from the overproduction of some hormones, such as growth hormone or cortisol. Additionally, due to the impact of high amounts of growth hormone on insulin synthesis, about 50% of people with acromegaly may develop insulin resistance or type 2 diabetes mellitus. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing number of hormonal diseases is driving the growth of the acromegaly market.

Emerging And High-Growth Segments In The Global Acromegaly Market
The acromegalymarket covered in this report is segmented –

1) By Type: Ectopic Acromegaly; Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement; Growth Hormone Suppression Test; Imaging; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
4) By Treatment: Medication; Somatostatin analogues; Dopamine Agonists; Growth Hormone Antagonist; Surgery; Radiation; Other Treatments
5) By End Users: Hospitals; Specialty Clinics; Homecare; Other End Users

Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly; Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess; Secondary Growth Hormone Excess

Acromegaly Market Future Trends
Major companies operating in the acromegaly market are focused on developing innovative products and solutions, such as generic lanreotide, to enhance treatment options and improve patient outcomes. Generic lanreotide refers to a non-branded formulation of the medication used to treat acromegaly and certain neuroendocrine tumors. It acts as a somatostatin analogue, reducing growth hormone secretion and improving patient accessibility to effective treatment options. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company focused on generic drugs, launched the first and only generic version of Sandostatin LAR Depot in the United States. The injectable suspension, octreotide acetate, is indicated for treating acromegaly and severe diarrhea associated with carcinoid syndrome. This introduction enhances access to crucial therapy for patients requiring these treatments.

Key Acromegaly Company Insights:
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

View the full acromegaly market report here:
Growth & Share Analysis

How Does Acromegaly Market Growth Vary Across Major Regions?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company